Ketamine inhibits tumor necrosis factor secretion by RAW264.7 murine macrophages stimulated with antibiotic-exposed strains of community-associated, methicillin-resistant Staphylococcus aureus

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Spentzas, Thomas ^a,b   Shapley, Rebekah K H ^a,b   Aguirre, Carlos A ^a,b   Meals, Elizabeth ^a,b   Lazar, Lauren ^a,b   Rayburn, Mark S ^a,b   Walker, Brett S ^a,b   English, B Keith ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; ANTIBIOTIC AGENT; DAPTOMYCIN; DIZOCILPINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TUMOR NECROSIS FACTOR; VANCOMYCIN; ANTIINFECTIVE AGENT; DIZOCILPINE MALEATE; N METHYLASPARTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL STIMULATION; COLONY FORMING UNIT; COMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INOCULATION; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SUPERNATANT; ANIMAL; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; ISOLATION AND PURIFICATION; MACROPHAGE ACTIVATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; SECRETION; TIME;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; DAPTOMYCIN; DIZOCILPINE MALEATE; DRUG SYNERGISM; KETAMINE; MACROPHAGE ACTIVATION; MACROPHAGES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; N-METHYLASPARTATE; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VANCOMYCIN;

EID: 78951478260     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-11     Document Type: Article

References (49)

1. Buckingham SC, McDougal LK, Cathey LD, Comeaux K, Craig AS, Fridkin SK, Tenover FC. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee children's hospital. Pediatr Infect Dis J 2004, 23:619-24. 10.1097/01.inf.0000131981.67342.c4, 15247599.
2. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-74. 10.1056/NEJMoa055356, 16914702.
3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama 2007, 298:1763-71. 10.1001/jama.298.15.1763, 17940231.
4. Centers for Disease Control and Prevention: Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999. MMWR 1999, 48:707-710.
5. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009, 9:384-92. 10.1016/S1473-3099(09)70133-1, 19467478.
6. Reed C, Kallen AJ, Patton M, Arnold KE, Farley MM, Hageman J, Finelli L. Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children. Pediatr Infect Dis J 2009, 28:572-6. 10.1097/INF.0b013e31819d8b71, 19478685.
7. Nygaard TK, DeLeo FR, Voyich JM. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors. Curr Opin Infect Dis 2008, 21:147-52. 10.1097/QCO.0b013e3282f64819, 18317037.
8. Nygaard TK, Pallister KB, Ruzevich P, Griffith S, Vuong C, Voyich JM. SaeR binds a consensus sequence within virulence gene promoters to advance USA300 pathogenesis. J Infect Dis 2010, 201:241-54. 10.1086/649570, 2798008, 20001858.
9. Assimacopoulos AP, Strandberg KL, Rotschafer JH, Schlievert PM. Extreme pyrexia and rapid death due to Staphylococcus aureus infection: analysis of 2 cases. Clin Infect Dis 2009, 48:612-4. 10.1086/597009, 2771751, 19191649.
10. Cavaillon JM, Adib-Conquy M. Monocytes/macrophages and sepsis. Crit Care Med 2005, 33:S506-9. 10.1097/01.CCM.0000185502.21012.37, 16340435.
11. English BK, Maryniw EM, Talati AJ, Meals EA. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob Agents Chemother 2006, 50:2225-7. 10.1128/AAC.01559-05, 1479096, 16723590.
12. Creel AM, Durham SH, Benner KW, Alten JA, Winkler MK. Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children. Pediatr Crit Care Med 2009, 10:323-7. 10.1097/PCC.0b013e3181988798, 19307811.
13. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007, 51:4255-60. 10.1128/AAC.00824-07, 2167999, 17923487.
14. Micklefield J. Daptomycin structure and mechanism of action revealed. Chem Biol 2004, 11:887-8. 10.1016/j.chembiol.2004.07.001, 15271343.
15. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009, 22:240-73. 10.1128/CMR.00046-08, 2668232, 19366914.
16. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002, 15:95-110. 10.1128/CMR.15.1.95-110.2002, 118062, 11781269.
17. Carcillo JA, Cunnion RE. Septic shock. Crit Care Clin 1997, 13:553-74. 10.1016/S0749-0704(05)70328-6, 9246530.
18. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. Jama 1991, 266:1242-5. 10.1001/jama.266.9.1242, 1870250.
19. Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002, 30:1365-78. 10.1097/00003246-200206000-00040, 12072696.
20. Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 2005, 6:S3-5. 10.1097/01.PCC.0000161289.22464.C3, 15857554.
21. Chang Y, Chen TL, Sheu JR, Chen RM. Suppressive effects of ketamine on macrophage functions. Toxicol Appl Pharmacol 2005, 204:27-35. 10.1016/j.taap.2004.08.011, 15781291.
22. Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U. Repeated injection of MK801: an animal model of schizophrenia?. Neurochem Int 2006, 48:541-6.
23. Kawasaki C, Kawasaki T, Ogata M, Nandate K, Shigematsu A. Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood. Can J Anaesth 2001, 48:819-23. 10.1007/BF03016701, 11546726.
24. Kawasaki T, Ogata M, Kawasaki C, Ogata J, Inoue Y, Shigematsu A. Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro. Anesth Analg 1999, 89:665-9. 10.1097/00000539-199909000-00024, 10475301.
25. Koga K, Ogata M, Takenaka I, Matsumoto T, Shigematsu A. Ketamine suppresses tumor necrosis factor-alpha activity and mortality in carrageenan-sensitized endotoxin shock model. Circ Shock 1994, 44:160-8.
26. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988, 57:505-18. 10.1146/annurev.bi.57.070188.002445, 3052281.
27. Cohen J, Abraham E. Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis 1999, 180:116-21. 10.1086/314839, 10353869.
28. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 2009, 16:3152-67. 10.2174/092986709788803024, 19689289.
29. Grewal IS. Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol 2009, 647:1-7. full_text, 19760063.
30. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, Golenbock DT. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999, 274:33419-25. 10.1074/jbc.274.47.33419, 10559223.
31. Kapetanovic R, Nahori MA, Balloy V, Fitting C, Philpott DJ, Cavaillon JM, Adib-Conquy M. Contribution of phagocytosis and intracellular sensing for cytokine production by Staphylococcus aureus-activated macrophages. Infect Immun 2007, 75:830-7. 10.1128/IAI.01199-06, 1828506, 17118979.
32. Morris RG. Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5. J Neurosci 1989, 9:3040-57.
33. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244:1360-2. 10.1126/science.2660263, 2660263.
34. Kudoh M, Sakai M, Shibuki K. Differential dependence of LTD on glutamate receptors in the auditory cortical synapses of cortical and thalamic inputs. J Neurophysiol 2002, 88:3167-74. 10.1152/jn.00928.2001, 12466438.
35. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351:950-3.
36. VF Feng N, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit 1995, 17:95-100. 10.1097/00007691-199502000-00016, 7725385.
37. Idvall J, Ahlgren I, Aronsen KR, Stenberg P. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 1979, 51:1167-73. 10.1093/bja/51.12.1167, 526385.
38. TS Parkin MC, Smith NW, Halket JM, Braithwaite RA, Elliott SP, Osselton MD, Cowan DA, Kicman AT. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J. Chrom 2008, B876:137-142.
39. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist 1975, 24:260-3.
40. Genever PG, Wilkinson DJ, Patton AJ, Peet NM, Hong Y, Mathur A, Erusalimsky JD, Skerry TM. Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood 1999, 93:2876-83.
41. Mukhin AG, Ivanova SA, Knoblach SM, Faden AI. New in vitro model of traumatic neuronal injury: evaluation of secondary injury and glutamate receptor-mediated neurotoxicity. J Neurotrauma 1997, 14:651-63. 10.1089/neu.1997.14.651, 9337127.
42. Pearce IA, Cambray-Deakin MA, Burgoyne RD. Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett 1987, 223:143-7. 10.1016/0014-5793(87)80525-2, 2889618.
43. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008, 198:1166-70. 10.1086/592053, 2574921, 18729780.
44. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989, 57:291-4. 313091, 2642470.
45. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-9. 10.1016/S0140-6736(02)07877-7, 11888586.
46. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J Infect Dis 2006, 194:1761-70. 10.1086/509506, 17109350.
47. Lombardi G, Miglio G, Dianzani C, Mesturini R, Varsaldi F, Chiocchetti A, Dianzani U, Fantozzi R. Glutamate modulation of human lymphocyte growth: in vitro studies. Biochem Biophys Res Commun 2004, 318:496-502. 10.1016/j.bbrc.2004.04.053, 15120628.
48. Gill R, Foster AC, Woodruff GN. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 1987, 7:3343-9.
49. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72:3666-70. 10.1073/pnas.72.9.3666, 433057, 1103152.